A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
Public ClinicalTrials.gov record NCT02493868. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms in participants with treatment-resistant depression (TRD) who are in stable remission after an induction and optimization course of intranasal esketamine plus an oral antidepressant.
Study identification
- NCT ID
- NCT02493868
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 719 participants
Conditions and interventions
Conditions
Interventions
- Esketamine Drug
- Placebo Drug
- Duloxetine (Oral Antidepressant) Drug
- Escitalopram (Oral antidepressant) Drug
- Sertraline (Oral Antidepressant) Drug
- Venlafaxine Extended Release (XR) (Oral Antidepressant) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 1, 2015 (Actual)
- Primary completion
- Feb 15, 2018 (Actual)
- Completion
- Feb 16, 2018 (Actual)
- Last update posted
- Apr 29, 2025
2015 – 2018
United States locations
- U.S. sites
- 53
- U.S. states
- 23
- U.S. cities
- 53
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Anaheim | California | — | — |
| Not listed | Garden Grove | California | — | — |
| Not listed | Glendale | California | — | — |
| Not listed | Oakland | California | — | — |
| Not listed | Orange | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | San Marcos | California | — | — |
| Not listed | San Rafael | California | — | — |
| Not listed | Hartford | Connecticut | — | — |
| Not listed | Bradenton | Florida | — | — |
| Not listed | Gainesville | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Hoffman Estates | Illinois | — | — |
| Not listed | Joliet | Illinois | — | — |
| Not listed | Maywood | Illinois | — | — |
| Not listed | Schaumburg | Illinois | — | — |
| Not listed | Skokie | Illinois | — | — |
| Not listed | Prairie Village | Kansas | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Lake Charles | Louisiana | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Gaithersburg | Maryland | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | New Bedford | Massachusetts | — | — |
| Not listed | Quincy | Massachusetts | — | — |
| Not listed | Watertown | Massachusetts | — | — |
| Not listed | Worcester | Massachusetts | — | — |
| Not listed | Rochester Hills | Michigan | — | — |
| Not listed | Minneapolis | Minnesota | — | — |
| Not listed | O'Fallon | Missouri | — | — |
| Not listed | Saint Charles | Missouri | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Durham | North Carolina | — | — |
| Not listed | Hickory | North Carolina | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Media | Pennsylvania | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Scranton | Pennsylvania | — | — |
| Not listed | Lincoln | Rhode Island | — | — |
| Not listed | Providence | Rhode Island | — | — |
| Not listed | Arlington | Texas | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Charlottesville | Virginia | — | — |
| Not listed | Waukesha | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 102 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02493868, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2025 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02493868 live on ClinicalTrials.gov.